title: [Treating severe dry eye syndromes with autologous serum].
abstract: BACKGROUND
  Dry eye syndrome with tear deficiency can be improved with artificial tears, which can be associated with topical anti-inflammatory agents. Autologous serum can provide the ocular surface with beneficial growth factors and vitamins.
  
  
  METHODS
  Twenty-one patients suffering from severe dry eye due to Sjögren's syndrome were treated with 20% autologous serum for 2 Months. The Schirmer I test, break-up time, and fluorescein and lissamine green stainings were performed before and after treatment. Subjective complaints such as burning, foreign body sensation, dryness and photophobia were assessed by a questionnaire as well as a face score reflecting the current condition of patients' eyes.
  
  
  RESULTS
  Lissamine green and fluorescein scores improved significantly as well as subjective symptoms of burning, foreign body sensation and dryness (p<0.05). The face score was significantly improved. Bacterial culture of serum delivered to the patients all remained negative.
  
  
  CONCLUSIONS
  Autologous serum provides growth factors and vitamins that are useful for an altered ocular surface due to Sjögren's disease. However, some problems still remain: risk of contamination, arbitrary dilution of autologous serum, and a current lack of regulations for use of autologous serum. A close collaboration between ophthalmologists and the Etablissement Français du Sang (French Blood Bank) is mandatory because autologous serum should be considered as a useful tool to treat severe ocular surface disorders.
  
  
  CONCLUSIONS
  The use of autologous serum improved symptoms and objective signs caused by severe Sjögren's syndrome. Currently, a lack of clear regulations prevents its widespread use in severe ocular surface disorders.
authors.affiliation: Service d'Ophtalmologie, CHU, 3, rue du Faubourg Raines, 21000 Dijon. catherine.creuzot-garcher@chu-dijon.fr
authors.forename: C
authors.initials: C
authors.lastname: Creuzot-Garcher
authors.forename: P-O
authors.initials: PO
authors.lastname: Lafontaine
authors.forename: F
authors.initials: F
authors.lastname: Brignole
authors.forename: P-J
authors.initials: PJ
authors.lastname: Pisella
authors.forename: P
authors.initials: P
authors.lastname: d'Athis
authors.forename: A
authors.initials: A
authors.lastname: Bron
authors.forename: V
authors.initials: V
authors.lastname: Lapierre
authors.forename: C
authors.initials: C
authors.lastname: Baudouin
mesh_terms: D001804:Blood Transfusion, Autologous; D015352:Dry Eye Syndromes / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D005451:Fluorescein Angiography; D006801:Humans; D010951:Plasma Exchange; D012859:Sjogren's Syndrome / Q000150:complications; D014787:Vision Tests